[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中国医学前沿杂志(电子版), 2019, 11(12):51-77. [2] 孙亚朦, 贾继东, 尤红. 2022年《扩大慢性乙型肝炎抗病毒治疗的专家意见》解读[J]. 中国临床医生杂志, 2022, 50(10):1144-1146. [3] LURIE Y, WEBB M, CYTTER-KUINT R,et,al. Non-invasive diagnosis of liver fibrosis and cirrhosis[J]. World J Gastroenterol, 2015, 21(41):11567-11583. [4] LIAW YF.Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(Suppl 1) : 100-107. [5] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J].中国肝脏病杂志(电子版), 2015, (3):1-18. [6] CHU CM, LIAW YF.Prognosis of immune-tolerant phase chronic hepatitis B[J]. Gut, 2018, 67(5):988-989. [7] 李强,黄玉仙,陈良.ALT正常的HBeAg阳性高病毒载量慢性HBV感染者明显肝组织学改变的独立预测因素[J].临床肝胆病杂志,2016,32(7):1210-1314. [8] GUI HL, WANG H,YANG YH,et,al. Significant histopathlolgy in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J]. J Viral Hepat, 2010, 17(Suppl 1):44-50. [9] DUAN M, CHI X, XIAO H, et al.High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. [10] KIM GA, LIM YS, HAN S, et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5):945-952. [11] CHOI GH, KIM GA, CHOI JG, et al.High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no signifificant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. [12] CHENG JL, WANG XL, YANG SG, et al.Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients[J]. World J Gastroenterol, 2017, 23(15):2802-2810. [13] 胡梦琳,潘爱萍,张雨,等.低水平谷丙转氨酶慢性HBV感染者135例肝脏病理特征及影响因素分析[J].中华临床感染病杂志,2020, 13(1):55-60. [14] 李晓月,李述捷,易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝癌的研究进展[J/CD].新发传染病电子杂志, 2022, 7(1):92-99. |